Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 29 min ago
Peer-reviewedCC BY 4.0Cornea

Antifungal Therapy for Fusarium Keratitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • Richard Farnan1,2
  • Alexander Ergun3
  • Gordon Farnan2
  • Aisling McGlacken Byrne1
  • Aram Saeed4
4 affiliations
  1. 1Department of Ophthalmology, University Hospital Galway, Galway, Ireland
  2. 2Royal College of Surgeons in Ireland, Dublin, Ireland
  3. 3Beacon Academy, Beacon Hospital, Dublin, Ireland ; and
  4. 4University of Galway, Galway, Ireland .
Read full textDOICite

Abstract

Purpose:: Fusarium keratitis is a leading cause of fungal corneal ulceration worldwide and is associated with substantial visual morbidity. Despite the availability of randomized controlled trial (RCT) data, optimal antifungal therapy remains debated. This study aims to define an evidence-based therapeutic hierarchy for F. keratitis using RCT evidence.

Methods:: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. MEDLINE, EMBASE, and CINAHL were searched from inception to December 2025 for RCTs evaluating antifungal therapies in fungal keratitis with extractable Fusarium-specific data. Two independent reviewers performed study selection, data extraction, and risk of bias assessment using the Cochrane Risk of Bias 2.0 tool. Random-effects meta-analysis (DerSimonian–Laird) was used to pool outcomes. The primary outcome was best spectacle-corrected visual acuity (BSCVA, LogMAR). Secondary outcomes included corneal perforation and requirement for therapeutic penetrating keratoplasty. Certainty of evidence was assessed using the GRADE framework.

Results:: Eleven RCTs comprising over 1800 participants were included. Meta-analysis demonstrated that topical natamycin 5% was associated with significantly improved visual acuity compared with topical voriconazole 1% (pooled mean difference −0.18 LogMAR, 95% confidence interval −0.30 to −0.05; I2 = 38%), corresponding to an improvement of approximately 2 Snellen lines. Natamycin was also associated with a substantial reduction in corneal perforation and requirement for therapeutic keratoplasty (pooled odds ratio 0.42, 95% confidence interval 0.22–0.80). The direction of effect was consistent across included trials, with low-to-moderate heterogeneity (I2 = 38%). Adjunctive systemic or intrastromal voriconazole did not demonstrate consistent benefit and was associated with increased adverse events. Evidence for alternative antifungal agents remains limited.

Conclusions:: Meta-analytic findings define a clear evidence-based therapeutic hierarchy in F. keratitis and establish topical natamycin 5% as the standard of care. Routine use of voriconazole is not supported in unselected patients. Further adequately powered, species-specific randomized trials are required to optimize treatment strategies in this vision-threatening condition.

Related

  1. Fusarium falciforme keratitis in a corneal transplant recipient treated successfully with fosmanogepix and intracameral amphotericin B
    Ashley Zeoli, Christine Shieh, Karen C. Bloch +5
    ASM case reportsPeer-reviewedCC BYFull text2 citedGeneral medicineEurope PMCPMC
  2. Sodium Butyrate Alleviates Fungal Keratitis by Exerting Antifungal Activity and Dampening Inflammation Through the Nrf2/HO-1 Axis
    Zhaoyang Zhang, Ziyue Zhang, Huijin Duan +6
    Investigative Ophthalmology & Visual SciencePeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  3. Tocilizumab in Acute Coronary Syndromes: A Systematic Review of Randomized Controlled Trials
    Muhammad Umair Iqbal, Hassan Askari, Ira Abid +3
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Topical herbal medicine as treatment for chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials
    Carrie Shao, Cassie Shao, Andrew Haggarty +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  5. Perioperative intravenous lidocaine for the prevention of chronic postsurgical pain: a systematic review and meta-analysis of randomized controlled trials
    Wei-Jing Zhu, Ran An, Qian-Yun Pang +1
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{farnan2026antifungal,
  title = {{Antifungal Therapy for Fusarium Keratitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials}},
  author = {Richard Farnan and Alexander Ergun and Gordon Farnan and Aisling McGlacken Byrne and Aram Saeed},
  journal = {Cornea},
  year = {2026},
  month = jun,
  doi = {10.1097/ico.0000000000004220},
  url = {https://doi.org/10.1097/ico.0000000000004220},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Antifungal Therapy for Fusarium Keratitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
AU  - Richard Farnan
AU  - Alexander Ergun
AU  - Gordon Farnan
AU  - Aisling McGlacken Byrne
AU  - Aram Saeed
PY  - 2026
DA  - 2026/06/26
JO  - Cornea
DO  - 10.1097/ico.0000000000004220
UR  - https://doi.org/10.1097/ico.0000000000004220
AB  - Purpose:: Fusarium keratitis is a leading cause of fungal corneal ulceration worldwide and is associated with substantial visual morbidity. Despite the availability of randomized controlled trial (RCT) data, optimal antifungal therapy remains debated. This study aims to define an evidence-based therapeutic hierarchy for F. keratitis using RCT evidence.  Methods:: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. MEDLINE, EMBASE, and CINAHL were searched from inception to December 2025 for RCTs evaluating antifungal therapies in fungal keratitis with extractable Fusarium-specific data. Two independent reviewers performed study selection, data extraction, and risk of bias assessment using the Cochrane Risk of Bias 2.0 tool. Random-effects meta-analysis (DerSimonian–Laird) was used to pool outcomes. The primary outcome was best spectacle-corrected visual acuity (BSCVA, LogMAR). Secondary outcomes included corneal perforation and requirement for therapeutic penetrating keratoplasty. Certainty of evidence was assessed using the GRADE framework.  Results:: Eleven RCTs comprising over 1800 participants were included. Meta-analysis demonstrated that topical natamycin 5% was associated with significantly improved visual acuity compared with topical voriconazole 1% (pooled mean difference −0.18 LogMAR, 95% confidence interval −0.30 to −0.05; I2 = 38%), corresponding to an improvement of approximately 2 Snellen lines. Natamycin was also associated with a substantial reduction in corneal perforation and requirement for therapeutic keratoplasty (pooled odds ratio 0.42, 95% confidence interval 0.22–0.80). The direction of effect was consistent across included trials, with low-to-moderate heterogeneity (I2 = 38%). Adjunctive systemic or intrastromal voriconazole did not demonstrate consistent benefit and was associated with increased adverse events. Evidence for alternative antifungal agents remains limited.  Conclusions:: Meta-analytic findings define a clear evidence-based therapeutic hierarchy in F. keratitis and establish topical natamycin 5% as the standard of care. Routine use of voriconazole is not supported in unselected patients. Further adequately powered, species-specific randomized trials are required to optimize treatment strategies in this vision-threatening condition.
SN  - 0277-3740
SN  - 1536-4798
ER  -